MEDIORGMedicamen Organics

₹33.3+4.23%

Market Cap

₹38.96 Cr

Stock P/E

9.63

ROCE

16.97%

ROE

18.13%

Book Value

₹25.11

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Medicamen Organics Ltd. shows no growth metrics and is significantly behind its peers in terms of profitability and efficiency. Among its peers, Sun Pharmaceutical Industries Ltd. emerges as a strong leader in growth and profitability, while companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. also display solid performance. Medicamen is not currently a viable investment option given its lack of financial metrics and performance indicators.

Key Points

• Medicamen has no reported financial metrics, making it difficult to assess its performance against peers.
• Sun Pharmaceutical leads in revenue growth and profitability metrics.
• Cipla and Dr. Reddy's are also strong performers with solid ROE and EPS numbers.
• Financially, Medicamen is at risk given its lack of metrics and performance data.

Top Performers

Sun Pharmaceutical Industries Ltd.

Leads in revenue growth (YoY: 8.42%) and has strong profitability (ROE: 16.13%).

Cipla Ltd.

Consistent growth (YoY: 13.28%) and solid profitability metrics (ROE: 16.63%).

Dr. Reddy's Laboratories Ltd.

Strong EPS growth (68.07) and high profitability (ROE: 21.76%).

Explore

Watchlists

Command Palette